Maute et al. (77) addressed affinity, specificity, and tumor penetration when determining whether PD-(L)1–directed immunotherapy could be improved with smaller, non-antibody therapeutics that could be radiolabeled and applied as a PET tracer. This evidence concerns the gene CD274 and neoplasm.